PMID- 31773897
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20200720
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 16
IP  - 2
DP  - 2020 Apr
TI  - S-1 plus cisplatin as first-line treatment of patients with advanced non-small 
      cell lung cancer in Taiwan.
PG  - e68-e73
LID - 10.1111/ajco.13294 [doi]
AB  - AIM: S-1 combined with cisplatin is known to be noninferior to taxanes plus 
      platinum as the first-line treatment for patients with advanced nonsmall cell 
      lung cancer (NSCLC) in the Japanese population. This study aimed to evaluate the 
      efficacy and safety profiles of oral S-1 plus cisplatin (SP) in Taiwanese 
      patients. METHODS: Patients with previously untreated stage IIIB or IV NSCLC were 
      prospectively recruited to receive 40-60 mg of S-1 twice daily on days 1-21 plus 
      60 mg/m(2) of cisplatin on day 8 in a 5-week cycle for up to six cycles. RESULTS: 
      A total of 55 patients from five cancer centers in Taiwan were enrolled. Among 
      the 46 evaluable patients, those administered with SP achieved disease control 
      rate of 69.6% (partial response, 19.6%; stable disease, 50.0%), with median 
      overall survival and progression-free survival (PFS) of 15.1 and 5.7 months, 
      respectively. Moreover, a better survival trend was observed in epidermal growth 
      factor receptor mutation-positive patients versus mutation-negative patients 
      treated with SP (PFS, 8.6 vs 5.6 months). The most commonly observed 
      treatment-related adverse events (AEs) were nausea (41.8%), followed by decreased 
      appetite, anemia, and diarrhea. Grade of >/=3 AEs related to the study treatment 
      occurred in 11 patients (20.0%). No febrile neutropenia or treatment-related 
      death was found in this study. CONCLUSIONS: This study demonstrated that SP is an 
      effective and safe first-line regimen for Taiwanese patients with advanced NSCLC.
CI  - (c) 2019 John Wiley & Sons Australia, Ltd.
FAU - Lai, Chun-Liang
AU  - Lai CL
AD  - Division of Pulmonology and Critical Care, Department of Internal Medicine, 
      Buddhish Dalin Tzu Chi Hospital, Chiayi, Taiwan.
AD  - School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan.
AD  - Institute of Molecular Biology, Department of Life Science, National Chung Cheng 
      University, Chiayi, Taiwan.
FAU - Wei, Yu-Fen
AU  - Wei YF
AD  - Division of Respiratory and Chest Medicine, E-Da Hospital/I-Shou University, 
      Kaohsiung, Taiwan.
AD  - Institute of Biotechnology and Chemical Engineering, I-Shou University, 
      Kaohsiung, Taiwan.
FAU - Hsia, Te-Chun
AU  - Hsia TC
AD  - Department of Respiratory Therapy, China Medical University Hospital, Taichung, 
      Taiwan.
FAU - Chang, Gee-Chen
AU  - Chang GC
AD  - Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans 
      General Hospital, Taichung, Taiwan and Faculty of Medicine, School of Medicine, 
      National Yang-Ming University, Taipei, Taiwan.
FAU - Wu, Jiun-Ting
AU  - Wu JT
AD  - Division of Respiratory and Chest Medicine, E-Da Cancer Hospital/I-Shou 
      University, Kaohsiung, Taiwan.
FAU - Chen, Jung-Yueh
AU  - Chen JY
AD  - Division of Respiratory and Chest Medicine, E-Da Hospital/I-Shou University, 
      Kaohsiung, Taiwan.
FAU - Chen, Yuh-Min
AU  - Chen YM
AUID- ORCID: 0000-0003-0585-8463
AD  - Department of Chest Medicine, Taipei Veterans General Hospital and School of 
      Medicine, National Yang-Ming University, Taipei, Taiwan.
LA  - eng
GR  - TTY Biopharm Co., Ltd. (Taipei, Taiwan)/
PT  - Journal Article
DEP - 20191126
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Combinations)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology
MH  - Cisplatin/pharmacology/*therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Oxonic Acid/pharmacology/*therapeutic use
MH  - Survival Analysis
MH  - Taiwan
MH  - Tegafur/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - S-1
OT  - chemotherapy
OT  - nonsmall cell lung cancer
OT  - single-arm prospective study
EDAT- 2019/11/28 06:00
MHDA- 2020/07/21 06:00
CRDT- 2019/11/28 06:00
PHST- 2019/03/04 00:00 [received]
PHST- 2019/10/26 00:00 [accepted]
PHST- 2019/11/28 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2019/11/28 06:00 [entrez]
AID - 10.1111/ajco.13294 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2020 Apr;16(2):e68-e73. doi: 10.1111/ajco.13294. Epub 2019 
      Nov 26.